|
|
Volumn 31, Issue 20, 2013, Pages 2548-2553
|
|
Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DECITABINE;
5 AZA 2' DEOXYCYTIDINE;
ANTINEOPLASTIC ANTIMETABOLITE;
AZACITIDINE;
DRUG DERIVATIVE;
ACUTE MYELOID LEUKEMIA;
ADOLESCENT;
ADULT;
AGED;
ANEMIA;
ANGINA PECTORIS;
ARTICLE;
CANCER CHEMOTHERAPY;
CANCER MORTALITY;
CHILD;
CONTROLLED STUDY;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TOLERABILITY;
ERYTHROCYTE;
FATIGUE;
FEMALE;
HIGH RISK PATIENT;
HUMAN;
INFANT;
INJECTION SITE PAIN;
LEUKEMIA REMISSION;
LEUKOPENIA;
LOW DRUG DOSE;
LOW RISK PATIENT;
MAJOR CLINICAL STUDY;
MALE;
MULTICENTER STUDY;
MULTIPLE ORGAN FAILURE;
MYELODYSPLASTIC SYNDROME;
NAUSEA;
NEUTROPENIA;
NEWBORN;
ONCOLOGICAL PARAMETERS;
OPEN STUDY;
OVERALL SURVIVAL;
PANCYTOPENIA;
PERIPHERAL EDEMA;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROGNOSIS;
RANDOMIZED CONTROLLED TRIAL;
THROMBOCYTE;
THROMBOCYTOPENIA;
TREATMENT DURATION;
COMPARATIVE STUDY;
CONTROLLED CLINICAL TRIAL;
DISEASE FREE SURVIVAL;
DOSE RESPONSE;
DRUG ADMINISTRATION;
KAPLAN MEIER METHOD;
MAXIMUM TOLERATED DOSE;
MIDDLE AGED;
MORTALITY;
PROPORTIONAL HAZARDS MODEL;
RISK ASSESSMENT;
SEVERITY OF ILLNESS INDEX;
SUBCUTANEOUS DRUG ADMINISTRATION;
SURVIVAL;
TREATMENT OUTCOME;
AGED;
ANTIMETABOLITES, ANTINEOPLASTIC;
AZACITIDINE;
DISEASE-FREE SURVIVAL;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
FEMALE;
HUMANS;
INJECTIONS, SUBCUTANEOUS;
KAPLAN-MEIER ESTIMATE;
MALE;
MAXIMUM TOLERATED DOSE;
MIDDLE AGED;
MYELODYSPLASTIC SYNDROMES;
PROGNOSIS;
PROPORTIONAL HAZARDS MODELS;
RISK ASSESSMENT;
SEVERITY OF ILLNESS INDEX;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
|
|
EID: 84883890647
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2012.44.6823 Document Type: Article |
|
Times cited : (100)
|
|
References (16)
|
